Angiotensin II (AII), the biologically active component of the renin- angiotensin system, has a variety of physiological effects in many tissues. In addition, AII is an important pathogenic factor in some forms of clinical and experimental hypertension. Currently, the cellular and molecular mechanism(s) of action of AII are not well understood. AII interacts with two pharmacologically distinct subtypes of cell-surface receptors, AT1 and AT2. AT1 receptors couple to specific G-proteins and mediate most, if not all, of the well known effects of AII. Recently several cDNA clones encoding the AII receptor subtype, AT1, have been isolated and characterized. An AT1 receptor PCR amplified fragment was utilized by our laboratory as a radiolabeled probe to isolate several distinct rat genomic AT1 receptor clones. Preliminary data suggest that there are at least two AII receptor genes. The long term goal of this project is to define the AII receptor gene family and to examine the molecular mechanisms that regulate the expression of these receptors.
The Specific Aims are: 1) Characterize, compare and contrast the two distinct rat genomic AII receptor clones by restriction mapping and sequencing. The genes will be expressed and their activities compared. A comparison of tissue specific expression of these genes will also be carried out; 2) The role of AII in the modulation of AII receptor gene expression will be investigated by quantitating and comparing steady state mRNA levels of AII receptors in vascular smooth muscle cells isolated from normotensive and spontaneously hypertensive rats and in tissues from intact rats of these strains infused with exogenous AII or treated with deoxycorticosterone (DOCA) salt. 3) The cis-regulatory mechanism involved in selectively directing the transcription of the AII receptor promoters will be investigated utilizing DNA-mediated gene transfer. These studies will contribute to our basic understanding of the molecular mechanisms underlying AII gene expression in normal animals and will investigate whether AII gene expression is altered in a genetic hypertensive model.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29HL048848-02
Application #
3473958
Study Section
Cardiovascular and Renal Study Section (CVB)
Project Start
1992-08-01
Project End
1997-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
Schools of Medicine
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Elton, Terry S; Martin, Mickey M; Sansom, Sarah E et al. (2011) miRNAs got rhythm. Life Sci 88:373-83
Belevych, Andriy E; Sansom, Sarah E; Terentyeva, Radmila et al. (2011) MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One 6:e28324
Nishijima, Yoshinori; Sridhar, Arun; Bonilla, Ingrid et al. (2011) Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology. Cardiovasc Res 91:71-9
Feldman, David; Elton, Terry S; Menachemi, Doron M et al. (2010) Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine. Vasc Health Risk Manag 6:387-97
Kuhn, Donald E; Nuovo, Gerard J; Terry Jr, Alvin V et al. (2010) Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J Biol Chem 285:1529-43
Elton, Terry S; Sansom, Sarah E; Martin, Mickey M (2010) Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins. RNA Biol 7:540-7
Sansom, Sarah E; Nuovo, Gerard J; Martin, Mickey M et al. (2010) miR-802 regulates human angiotensin II type 1 receptor expression in intestinal epithelial C2BBe1 cells. Am J Physiol Gastrointest Liver Physiol 299:G632-42